Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

NCT07261631 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma
Non-Small Cell Lung Cancer
HR+/HER2- Ductal and Lobular Breast Cancer
Triple Negative Breast Cancer
Colorectal Cancer
Soft Tissue Sarcoma

Interventions

DRUG: 68Ga-NNS309
DRUG: 177Lu-DFC413

Sponsor

Novartis Pharmaceuticals